Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894061 · ClinicalTrials.gov registry record · Phase 2
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01894061 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01894061, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. The NovoTTF-l00A is a portable battery operated device which produces TTFields within the human body using surface electrodes (transducer arrays). Intermediate frequency electric fields (TTFields) stunt the growth of tumor cells. The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naive (meaning have never received bevacizumab before) patients with recurrent glioblastoma (GBM) as measured by 6-month progression free survival.
Interventions
- BIOLOGICAL Bevacizumab
- OTHER Quality of Life Assessment
- DEVICE NovoTTF-l00A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-09-18 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894061
The ClinicalTrials.gov registry entry for NCT01894061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01894061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01894061 about?
NCT01894061 is a clinical study titled "NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma". NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. The NovoTTF-l00A is a portable battery operated device which produces TTFields within the human body using surfa...
What is the current status of trial NCT01894061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-09-18. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT01894061?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Quality of Life Assessment (OTHER), NovoTTF-l00A (DEVICE).
Who is sponsoring clinical trial NCT01894061?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.